We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Renal Cell Carcinoma

Journal Scan / Research · May 24, 2022

Effect of BMI on Survival Outcome of Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

European Urology Open Science


Additional Info

Disclosure statements are available on the authors' profiles:

European Urology Open Science
Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis
Eur Urol Open Sci 2022 May 01;39(2022)62-71, K Takemura, S Yonekura, LE Downey, D Evangelopoulos, DYC Heng

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading